Replacement therapy with C1 esterase inhibitors for hereditary angioedema

Drugs of Today

Volumn 46, Issue 11, 2010, Pages 867-874

  Cicardi, Marco ^a   Zanichelli, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DIARRHEA; DISEASE SEVERITY; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; HUMAN; IMMUNOGENICITY; INJECTION SITE REDNESS; LARYNX EDEMA; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; RABBIT; RECOMMENDED DRUG DOSE; REVIEW; SKIN SWELLING; SYMPTOM; TRANSGENIC ANIMAL; URINE RETENTION; URTICARIA; VIDEOENDOSCOPY; VOMITING; ANIMAL; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DESIGN; GENETICS;

ANGIOEDEMAS, HEREDITARY; ANIMALS; ANIMALS, GENETICALLY MODIFIED; COMPLEMENT C1 INACTIVATOR PROTEINS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; RABBITS;

EID: 79955870080     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.11.1534012     Document Type: Review

References (50)

1. Levy, L.R., Lepow, I.H. Assay and properties of serum inhibitor of C′I-esterase. Proc Soc Exp Biol Med 1959, 101: 608-11.
2. Donaldson, V.H., Evans, R.R. A biochemical abnormality in herediatry angioneurotic edema: Absence of serum inhibitor of C′ 1-esterase. Am J Sci 1963, 31: 37-44.
3. Pickering, R.J., Good, R.A., Kelly, J.R., Gewurz, H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969, 1(7590): 326-30.
4. Vogelaar, E.F., Brummelhuis, H.G., Krijnen, H.W. Contributions to the optimal use of human blood. 3. Large-scale preparation of human c1 esterase inhibitor concentrate for clinical use. Vox Sang 1974, 26(2): 118-27.
5. Marasini, B., Cicardi, M., Agostoni, A. [Treatment of hereditary angioedema with a plasmatic concentrate of C1 esterase inhibitor]. Boll Soc Ital Cardiol 1976, 21(8): 1449-52.
6. Cicardi, M., Zingale, L.C., Zanichelli, A., Deliliers, D.L., Caccia, S. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007, 8(18): 3173-81.
7. Cicardi, M., Zingale, L., Zanichelli, A., Pappalardo, E., Cicardi, B. C1 inhibitor. Molecular and clinical aspects. Springer Semin Immunopathol 2005, 27(3): 286-98.
8. Lomas, D.A. Molecular mousetraps, alpha1-antitrypsin deficiency and the serpinopathies. Clin Med (London) 2005, 5(3): 249-57.
9. Beinrohr, L., Harmat, V., Dobo, J., Lorincz, Z., Gal, P., Zavodszky, P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007, 282(29): 21100-9.
10. Coutinho, M., Aulak, K.S., Davis, A.E. 3rd. Functional analysis of the serpin domain of C1 inhibitor. J Immunol 1994, 153(8): 3648-54.
11. Bock, S.C., Skriver, K., Nielsen, E. et al. Human C1 inhibitor: Primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986, 25(15): 4292-301.
12. Curd, J.G., Prograis, L.J. Jr., Cochrane, C.G. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 1980, 152(3): 742-7.
13. Fields, T., Ghebrehiwet, B., Kaplan, A.P. Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 1983, 72(1): 54-60.
14. Schapira, M., Silver, L.D., Scott, C.F. et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983, 308(18): 1050-3.
15. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., Agostoni, A. Plasma bradykinin in angio-oedema. Lancet 1998, 351(9117): 1693-7.
16. Han, E.D., MacFarlane, R.C., Mulligan, A.N., Scafidi, J., Davis, A.E. 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002, 109(8): 1057-63.
17. Kaplan, A.P., Joseph, K., Silverberg, M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002, 109(2): 195-209.
18. Caliezi, C., Zeerleder, S., Redondo, M. et al. C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Crit Care Med 2002, 30(8): 1722-8.
19. Donaldson, V.H., Rosen, F.S., Bing, D.H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians 1977, 90: 174-83.
20. Kleniewski, J., Blankenship, D.T., Cardin, A.D., Donaldson, V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992, 120(1): 129-39.
21. Donaldson, V.H., Rosen, F.S. Action of complement in hereditary angioneurotic edema: The role of C′1-esterase. J Clin Invest 1964, 43: 2204-13.
22. Donaldson, V.H. Mechanisms of activation of C′1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med 1968, 127(3): 411-29.
23. Donaldson, V.H., Ratnoff, O.D., Dias Da Silva, W., Rosen, F.S. Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J Clin Invest 1969, 48(4): 642-53.
24. Donaldson, V.H. Kinin formation in hereditary angioneurotic edema (HANE) plasma. Int Arch Allergy Appl Immunol 1973, 45(1): 206-9.
25. De Serres, J., Groner, A., Lindner, J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apher Sci 2003, 29(3): 247-54.
26. Terpstra, F.G., Kleijn, M., Koenderman, A.H. et al. Viral safety of C1-inhibitor NF. Biologicals 2007, 35(3): 173-81.
27. Ward, H.J., MacKenzie, J.M., Llewelyn, C.A. et al. Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. Vox Sang 2009, 97(3): 207-10.
28. Yunoki, M., Tanaka, H., Urayama, T. et al. Infectious prion protein in the filtrate even after 15 nm filtration. Biologicals 2010, 38(2): 311-3.
29. Longhurst, H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008, 9(3): 310-23.
30. Koles, K., van Berkel, P.H., Pieper, F.R. et al. N- And O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004, 14(1): 51-64.
31. Minta, J.O. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J Immunol 1981, 126(1): 245-9.
32. van Doorn, M.B., Burggraaf, J., van Dam, T. et al. A phase I study of recombinant human G inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005, 116(4): 876-83.
33. Martinez-Saguer, I., Rusicke, E., Aygoren-Pursun, E., von Hentig, N., Klingebiel, T., Kreuz, W. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: A prospective study. Transfusion 2010, 50(2): 354-60.
34. Gesuete, R., Storini, C., Fantin, A. et al. Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol 2009, 66(3): 332-42.
35. Bork, K., Staubach, P., Hardt, J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008, 63(6): 751-7.
36. Bork, K., Meng, G., Staubach, P., Hardt, J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005, 45(11): 1774-84.
37. Bork, K., Barnstedt, S.E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001, 161(5): 714-8.
38. Agostoni, A., Cicardi, M. Hereditary and acquired C1-inhibitor deficiency. Biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992, 71(4): 206-15.
39. Krassilnikova, S., Craig, E.T., Craig, T.J. Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2). Expert Rev Clin Immunol 2010, 6(3): 327-34.
40. Craig, T.J., Levy, R.J., Wasserman, R.L. et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009, 124(4): 801-8.
41. Kreuz, W., Martinez-Saguer, I., Aygoren-Pursun, E., Rusicke, E., Heller, C., Klingebiel, T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009, 49(9): 1987-95.
42. Levi, M., Choi, G., Picavet, C., Hack, C. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006, 117(4): 904-8.
43. Waytes, A.T., Rosen, F.S., Frank, M.M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996, 334(25): 1630-4.
44. Zuraw, B., Busse, P., White, M. et al. Efficacy and safety of long-term prophylaxis with C1 inhibitor (C1INH) concentrate in patients with hereditary angioedema (HAE). J Allergy Clin Immunol 2008, 121(1): S272.
45. Peyvandi, F., Palla, R., Menegatti, M., Mannucci, P.M. Introduction. Rare bleeding disorders: General aspects of clinical features, diagnosis, and management. Semin Thromb Hemost 2009, 35(4): 349-55.
46. Quastel, M., Harrison, R., Cicardi, M., Alper, C.A., Rosen, F.S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983, 71(4): 1041-6.
47. Cicardi, M., Zingale, L.C., Zanichelli, A. A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (ecallantide), a potent human plasma kallikrein inhibitor: A case study. Mol Immunol 2007, 44(1-3): 160-1.
48. Cicardi, M., Mannucci, P.M., Castelli, R., Rumi, M.G., Agostoni, A. Reduction in transmission of hepatitis C offer the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion 1995, 35(3): 209-12.
49. Choi, G., Soeters, M.R., Farkas, H. et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007, 47(6): 1028-32.
50. Varga, L., Farkas, H. Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor. Expert Rev Clin Immunol 2008, 4(6): 653-61.